Oncotype DX Colon Recurrence Score
Use
The Oncotype DX Colon Recurrence Score test is designed to quantify the risk of recurrence in patients with stage II, MMR-P, and stage III A/B colon cancer. By evaluating the gene expression of a patient's tumor, it helps to guide treatment decisions by assessing the likelihood of cancer recurrence. This assists in tailoring treatment plans specifically to the patient's risk profile, offering a more personalized approach to colon cancer treatment and management.
Special Instructions
Each patient has a unique risk profile, making the treatment decision different for everyone. The test involves analyzing the biology of the tumor to provide insight into recurrence risk, aiding in selecting appropriate post-surgery management strategies.
Limitations
The test is applicable to patients diagnosed with stage II, MMR-P, and stage III A/B colon cancer and may not be applicable to other cancer stages or types. Results may be influenced by the biological diversity of tumors, and the test does not replace the need for professional medical judgment in conjunction with other diagnostic tools and considerations.
Methodology
Other
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Tissue
Volume
Not provided
Minimum Volume
Not provided
Other tests from different labs that may be relevant